Aligos Therapeutics annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Aligos Therapeutics Depreciation & Amortization Growth & History (ALGS)
Aligos Therapeutics's depreciation and amortization was $930,000 for fiscal 2025.
View full Aligos Therapeutics company overviewAligos Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $930,000 | −$97,000 | −9.44% |
| 2024 | 2024-12-31 | $1.0M | −$532,000 | −34.12% |
| 2023 | 2023-12-31 | $1.6M | −$747,000 | −32.39% |
| 2022 | 2022-12-31 | $2.3M | −$713,000 | −23.62% |
| 2021 | 2021-12-31 | $3.0M | $284,000 | +10.38% |
| 2020 | 2020-12-31 | $2.7M | $1.3M | +95.92% |
| 2019 | 2019-12-31 | $1.4M | — | — |
Aligos Therapeutics quarterly depreciation and amortization
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $300,000 | $0 | 0.00% |
| Q1 2026 | 2026-03-31 | $346,000 | $152,000 | +78.35% |
| Q4 2025 | 2025-12-31 | $749,000 | — | — |
| Q3 2025 | 2025-09-30 | $200,000 | −$100,000 | −33.33% |
| Q2 2025 | 2025-06-30 | $300,000 | $0 | 0.00% |
| Q1 2025 | 2025-03-31 | $194,000 | −$88,000 | −31.21% |
| Q3 2024 | 2024-09-30 | $300,000 | $0 | 0.00% |
| Q2 2024 | 2024-06-30 | $300,000 | −$100,000 | −25.00% |
| Q1 2024 | 2024-03-31 | $282,000 | −$172,000 | −37.89% |
| Q3 2023 | 2023-09-30 | $300,000 | −$200,000 | −40.00% |
| Q2 2023 | 2023-06-30 | $400,000 | −$200,000 | −33.33% |
| Q1 2023 | 2023-03-31 | $454,000 | −$222,000 | −32.84% |
| Q3 2022 | 2022-09-30 | $500,000 | −$300,000 | −37.50% |
| Q2 2022 | 2022-06-30 | $600,000 | −$200,000 | −25.00% |
| Q1 2022 | 2022-03-31 | $676,000 | −$65,000 | −8.77% |
| Q3 2021 | 2021-09-30 | $800,000 | $92,000 | +12.99% |
| Q2 2021 | 2021-06-30 | $800,000 | $120,000 | +17.65% |
| Q1 2021 | 2021-03-31 | $741,000 | $410,000 | +123.87% |
| Q3 2020 | 2020-09-30 | $708,000 | $321,000 | +82.95% |
| Q2 2020 | 2020-06-30 | $680,000 | — | — |
| Q1 2020 | 2020-03-31 | $331,000 | — | — |
| Q3 2019 | 2019-09-30 | $387,000 | — | — |
Aligos Therapeutics depreciation and amortization trends
Over the last five fiscal years, Aligos Therapeutics's depreciation and amortization decreased from $2.7M to $930,000, a change of −$1.8M. The latest reported quarter, Q2 2026, shows $300,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aligos Therapeutics source filings ↗